- Home
- AMSC vs OCS Comparison
AMSC vs OCS Comparison
Compare AMSC & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSC
- OCS
- Stock Information
- Founded
- AMSC 1987
- OCS 2003
- Country
- AMSC United States
- OCS Switzerland
- Employees
- AMSC N/A
- OCS N/A
- Industry
- AMSC Metal Fabrications
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- AMSC Consumer Discretionary
- OCS Health Care
- Exchange
- AMSC Nasdaq
- OCS Nasdaq
- Market Cap
- AMSC 1.0B
- OCS 944.2M
- IPO Year
- AMSC 1991
- OCS N/A
- Fundamental
- Price
- AMSC $25.19
- OCS $22.61
- Analyst Decision
- AMSC Strong Buy
- OCS Strong Buy
- Analyst Count
- AMSC 3
- OCS 5
- Target Price
- AMSC $31.67
- OCS $28.80
- AVG Volume (30 Days)
- AMSC 881.9K
- OCS 132.2K
- Earning Date
- AMSC 02-05-2025
- OCS 03-17-2025
- Dividend Yield
- AMSC N/A
- OCS N/A
- EPS Growth
- AMSC N/A
- OCS N/A
- EPS
- AMSC N/A
- OCS N/A
- Revenue
- AMSC $176,142,000.00
- OCS $1,027,571.00
- Revenue This Year
- AMSC $47.52
- OCS $6.21
- Revenue Next Year
- AMSC $18.53
- OCS $760.04
- P/E Ratio
- AMSC N/A
- OCS N/A
- Revenue Growth
- AMSC 46.93
- OCS N/A
- 52 Week Low
- AMSC $10.19
- OCS $10.55
- 52 Week High
- AMSC $38.02
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- AMSC 42.28
- OCS 72.16
- Support Level
- AMSC $24.71
- OCS $22.53
- Resistance Level
- AMSC $28.35
- OCS $23.01
- Average True Range (ATR)
- AMSC 1.56
- OCS 0.34
- MACD
- AMSC -0.22
- OCS -0.14
- Stochastic Oscillator
- AMSC 13.46
- OCS 68.42
About AMSC American Superconductor Corporation
American Superconductor Corp generates the ideas, technologies, and solutions that meet world's demand for smarter, cleaner and energy. Through its Windtec Solutions, the company enables manufacturers to launch wind turbines quickly, effectively and profitably. Through its Gridtec Solutions, the company provides engineering planning services and grid systems that optimize network reliability, efficiency and performance. The company's segment includes Grid and Wind. It generates maximum revenue from the Grid segment.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.